Antinociception from lateral hypothalamic stimulation may be mediated by NK(1) receptors in the A7 catecholamine cell group in rat.
Stimulation of the lateral hypothalamus (LH) produces antinociception that is modified by intrathecal alpha-adrenergic antagonists. Spinally-projecting noradrenergic neurons in the LH have not been identified, suggesting that the LH may innervate brainstem noradrenergic neurons, such as the A7 catecholamine cell group in the dorsolateral pontine tegmentum, that modify nociception at the level of the spinal cord dorsal horn. Recently we demonstrated in neuroanatomical studies that substance P-immunoreactive neurons in the LH project the A7 area. To identify a functional connection between substance P neurons in the LH and the A7 cell group, the cholinergic agonist carbachol (125 nmol) was microinjected into the LH of female Sprague-Dawley rats and antinociception was obtained on the tail flick or foot withdrawal test. Cobalt chloride (100 nM) was then microinjected near the A7 cell group to block synaptic activation of spinally-projecting A7 neurons, which were identified using tyrosine-hydroxylase immunoreactivity. Within 5 min of the cobalt chloride injection, the antinociceptive effect of carbachol stimulation was blocked. In another set of experiments, the NK(1) receptor antagonist L-703-606 (5 microg) was microinjected near the A7 cell group following LH stimulation with carbachol. L-703-606 also abolished LH-induced antinociception. These results support the conclusion that antinociception produced by activating substance P neurons in the LH is mediated in part by the subsequent activation of spinally-projecting noradrenergic neurons in the A7 cell group.
Holden
Janean E
JE
Department of Medical-Surgical Nursing, The University of Illinois at Chicago, 718 College of Nursing (M/C 802), 845 S. Damen Avenue, Chicago, IL 60612-7350, USA. jeholden@uic.edu
Van Poppel
Angela Y
AY
Thomas
Sarah
S
D000818:Animals; D016587:Antimutagenic Agents / Q000494:pharmacology; D002217:Carbachol / Q000494:pharmacology; D002395:Catecholamines / Q000502:physiology*; D018679:Cholinergic Agonists / Q000494:pharmacology; D003035:Cobalt / Q000494:pharmacology; D005260:Female; D007026:Hypothalamic Area, Lateral / Q000166:cytology / Q000502:physiology*; D008845:Microinjections; D009434:Neural Pathways; D064729:Neurokinin-1 Receptor Antagonists; D009619:Nociceptors / Q000187:drug effects / Q000502:physiology*; D017288:Pain Threshold / Q000502:physiology; D011149:Pons / Q000166:cytology / Q000502:physiology*; D011812:Quinuclidines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018040:Receptors, Neurokinin-1 / Q000378:metabolism*
D016587:Antimutagenic Agents; D002395:Catecholamines; D018679:Cholinergic Agonists; D064729:Neurokinin-1 Receptor Antagonists; D011812:Quinuclidines; D018040:Receptors, Neurokinin-1; C076851:L 703606; D003035:Cobalt; D002217:Carbachol; C018021:cobaltous chloride